CLINICAL CHARACTERISTICS OF A GROUP OF PATIENTS WITH CTLA4 HAPLOINSUFFICIENCY SYNDROME: EXPERIENCE OF ONE CENTER
| Autor: | Alexandra Laberko, E.V. Raykina, G.N. Tereshenko, V.I. Burlakov, A.A. Roppelt, E.V. Deripapa, D.V. Bogdanova, Yu.A. Rodina, I.N. Abramova, Immunology named after Dmitry Rogachev, Moscow, Russia, A.Yu. Shcherbina, D.V. Yukhacheva, Anna Mukhina, D.S. Abramov, A.L. Khoreva, O.A. Shvets, Dmitry Pershin, M.Yu. Alexenko, A. M. Kieva, V.A. Vedmedskia, A.V. Pshonkin, G.G. Solopova |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Pediatria. Journal named after G.N. Speransky. 100:22-30 |
| ISSN: | 1990-2182 0031-403X |
| Popis: | CTLA4 deficiency is a primary immunodeficiency state (PIDS) caused by monoallelic mutations in the gene of the same name, and belongs to the group of immunodeficiencies with immune dysregulation. This work analyzes the results of 11 patients with CTLA4 mutations observed at the Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from October 2012 to January 2021. In 10 of 11 patients had some manifestations of immune dysregulation, the most frequent were cytopenias (10/11), lymphoproliferation (9/11) and lung damage caused by the type of interstitial lymphocytic lungs disease (9/11). Almost all patients had such abnormal immune parameters as hypogammaglobulinemia or dysgammaglobulinemia, lymphopenia. Currently, there is no standardized treatment for these patients, however, targeted therapy with biologically modified CTLA4 is a promising approach to the treatment of autoimmune complications in patients with CTLA4 deficiency. The only curative treatment option for patients with PIDS is hematopoietic stem cell transplantation, but in order to make conclusions about the effectiveness and safety of this treatment, a long period of observation and large groups of patients are required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|